Abstract
Ticagrelor is an orally active, reversibly bind of the P2Y12 receptor that can prevent ADP-mediated platelet activation and has a faster onset of action than clopidogrel. A stability-indicating HPLC method for the determination of ticagrelor in coated tablets was developed and validated. Chromatographic analysis was performed in a Shimadzu liquid chromatograph, equipped with Phemomenex® C18 column (250 x 4.6 mm, 5 μm), using a mobile phase composed of acetonitrile: water with 0.5% triethylamine (57:43 v/v) pH 7.0, at 0.7 ml/min flow rate and injection volume of 20 μl. Under the conditions established, the method demonstrated to be specific, without interference from formulation excipients, stability- indicating, linear (r = 0.9990) in the concentration range of 45.0 to 105.0 μg/ml, precise (RSD=0.71), accurate (99.61% of mean recovery) and robust. It can be successfully applied to ticagrelor tablets quality control, being adequate for routine analysis.
Keywords: Antiplatelet, HPLC, quality control, stability-indicating assay, tablets, ticagrelor.
Current Pharmaceutical Analysis
Title:Determination of the New Antiplatelet Agent Ticagrelor in Tablets by Stability-Indicating HPLC Method
Volume: 10 Issue: 4
Author(s): Caren Gobetti, Rubia Lazzaretti Pereira, Andreas Sebastian Loureiro Mendez and Cássia Virginia Garcia
Affiliation:
Keywords: Antiplatelet, HPLC, quality control, stability-indicating assay, tablets, ticagrelor.
Abstract: Ticagrelor is an orally active, reversibly bind of the P2Y12 receptor that can prevent ADP-mediated platelet activation and has a faster onset of action than clopidogrel. A stability-indicating HPLC method for the determination of ticagrelor in coated tablets was developed and validated. Chromatographic analysis was performed in a Shimadzu liquid chromatograph, equipped with Phemomenex® C18 column (250 x 4.6 mm, 5 μm), using a mobile phase composed of acetonitrile: water with 0.5% triethylamine (57:43 v/v) pH 7.0, at 0.7 ml/min flow rate and injection volume of 20 μl. Under the conditions established, the method demonstrated to be specific, without interference from formulation excipients, stability- indicating, linear (r = 0.9990) in the concentration range of 45.0 to 105.0 μg/ml, precise (RSD=0.71), accurate (99.61% of mean recovery) and robust. It can be successfully applied to ticagrelor tablets quality control, being adequate for routine analysis.
Export Options
About this article
Cite this article as:
Gobetti Caren, Pereira Lazzaretti Rubia, Mendez Sebastian Loureiro Andreas and Garcia Virginia Cássia, Determination of the New Antiplatelet Agent Ticagrelor in Tablets by Stability-Indicating HPLC Method, Current Pharmaceutical Analysis 2014; 10 (4) . https://dx.doi.org/10.2174/1573412910666140610211656
DOI https://dx.doi.org/10.2174/1573412910666140610211656 |
Print ISSN 1573-4129 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-676X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neonatal Persistent Pulmonary Hypertension Associated with Congenital Cystic Adenomatoid Malformation Treated with Sildenafil: Case Report
Current Pediatric Reviews The Role of Scaffolding in Standard Mechanism Serine Proteinase Inhibitors
Protein & Peptide Letters The Chemistry and Bio-Medicinal Significance of Pyrimidines & Condensed Pyrimidines
Current Topics in Medicinal Chemistry Aminopyridines and Acetyl-DL-leucine: New Therapies in Cerebellar Disorders
Current Neuropharmacology Role of Insulin Signaling in the Interaction Between Alzheimer Disease and Diabetes Mellitus: A Missing Link to Therapeutic Potential
Current Aging Science Neurodegeneration and Neurogenesis: Focus on Alzheimers Disease
Current Alzheimer Research Influence of Statin Use on Endothelial Function: From Bench to Clinics
Current Pharmaceutical Design Antenatal Hypoxia and Pulmonary Vascular Function and Remodeling
Current Vascular Pharmacology The Gut and Intestinal Bacteria in Chronic Heart Failure
Current Drug Metabolism Association between Red Blood Cell Distribution Width and Pulmonary Function among Iranian Employees
Current Respiratory Medicine Reviews Clinical Significance of the Cardio-Ankle Vascular Index (CAVI) in Hypertension
Current Hypertension Reviews The Medicinal Chemistry of Nitrite as a Source of Nitric Oxide Signaling
Current Topics in Medicinal Chemistry Combination Therapy of Cisplatin and other Agents for Osteosarcoma: A Review
Current Cancer Therapy Reviews Topomer CoMFA and Virtual Screening Studies of Azaindole Class Renin Inhibitors
Combinatorial Chemistry & High Throughput Screening New Insights into the Regulation of Liver Inflammation and Oxidative Stress
Mini-Reviews in Medicinal Chemistry Current Issues with Glycoprotein IIb-IIIa Antagonists
Current Drug Targets Potential Role of Cardiovascular Imaging in Improving Cardiovascular Outcome in Coronary Artery Disease
Current Pharmaceutical Design MIP-1α and MCP-1 Induce Migration of Human Umbilical Cord Blood Cells in Models of Stroke
Current Neurovascular Research The Challenges Involved in Modeling Toxicity Data In Silico: A Review
Current Pharmaceutical Design Is there a Rational Approach for Increasing Drug Specificity? Considerations on CNS Target Choice and Validation
Recent Patents on CNS Drug Discovery (Discontinued)